RxDoctor Payments Data

Sherry Ma, MD

Neurology · Saint Louis, MONPI 1275649048

Payments from drug & device makers

$1,698in general payments, 2019–2025

Across 25 payments — averaging $67.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$250
  • Lilly USA, LLC$184
  • EMD Serono, Inc.$148
  • Amgen$145
  • AbbVie$137
  • SK Life Science, Inc.$130
  • plus $705 from 8 others

What the payments were for

  • Food & beverage$1,698100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,698 in reported general payments places this provider in the 50th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$50,243
Medicare patients
241
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant15$15,465
Carbamazepine ErCarbamazepine36$3,831
Mycophenolate Mofetil21$2,792
Carbamazepine38$2,097
Carbidopa-LevodopaCarbidopa/Levodopa82$1,587
Donepezil Hcl91$1,416
Levetiracetam30$1,301
Pregabalin32$1,051
Memantine Hcl26$851
Ropinirole Hcl37$758
Gabapentin42$731
Baclofen15$537
Duloxetine Hcl34$526
Divalproex Sodium16$496
Memantine Hcl ErMemantine Hcl12$401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$137$15,46515 claims
Lilly USA, LLCOlanzapine$184$12113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 381 neurology providers in Missouri.

Other neurology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →